Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine if the Midazolam-Meperidine-Dexmedetomidine is Superior to the Midazolam-Meperidine for Sedation During ERCP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Those who are admitted for diagnostic and therapeutic ERCPs~* aged 20 to 80 years~* American Society of Anesthesiologists (ASA) classification I to III~Exclusion Criteria:~* ASA physical status IV and V~* allergic to any components of sedation and opioid drugs~* patients with chronic illicit drug use

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Midazolam-Meperidine-Dexmedetomidine (Type: EXPERIMENTAL): midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and dexmedetomidine 1μg/Kg•hr infusion (30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)
- Midazolam-Meperidine (Type: SHAM_COMPARATOR): midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and placebo(saline) infusion(30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)

Based on this trial design, predict the completion outcome and termination type (if applicable).